Logo Image

Merve Tokocin

Articles by Merve Tokocin

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

ByMutlu Dogan,Berk Goktepe,Mehmet Bilici,Sercan Aksoy,Fatih Selcukbiricik,Ali Alkan,Arzu Oguz,Arzu Yasar,Naziye Ak,Betul Ersoz,Lutfi Dogan,Merve Tokocin,Yasemin Evlendi,Ozlem Soran,Qurat Ul Ain Sabih,Julia Foldi,Atilla Soran, MD, MPH

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

Latest Updated Articles